Table 1.
Estimation of the % of inhibition of the SARS-CoV-2 replication by fixed-doses of ACT (1x corresponds to expected maximum blood concentration (Cmax) for each ACT drug at doses commonly administered in malaria treatment)
| Inhibition % at 2x plasma Cmax | Inhibition % at 1x plasma Cmax | Inhibition % at 0.5x plasma Cmax | ||||
|---|---|---|---|---|---|---|
| Combination | Concentrations | Mean ± SD | Concentrations | Mean ± SD | Concentrations | Mean ± SD |
| Mefloquine-dihydroartemisinin | 8.3-5 μM | 99.6 ± 0.7 | 4.1-2.5 μM | 72.1 ± 18.3 | 2.0-1.25 μM | 30.9 ± 14.1 |
| Desethylamodiaquine-dihydroartemisinin | 4.0-5.0 μM | 85.8 ± 9.9 | 2.0-2.5 μM | 32.3 ± 9.9 | 1.0-1.25 μM | 17.2 ± 6.5 |
| Pyronaridine-dihydroartemisinin | 0.5-1.0 μM | 38.2 ± 5.7 | 0.25-0.5 μM | 34.1 ± 7.1 | 0.12-0.25 μM | 16.3 ± 5.0 |
| Lumefantrine-dihydroartemisinin | 33.0-2.0 μM | 37.7 ± 3.4 | 16.5-0.5 μM | 27.1 ± 6.0 | 8.2-0.25 μM | 12.3 ± 4.4 |
| Piperaquine-dihydroartemisinin | 1.0-3.1 μM | 29.7 ± 16.8 | 0.5-1.5 μM | 29.3 ± 4.6 | 0.25-0.75 μM | 14.0 ± 4.2 |
SD = standard deviation